


Immuno modulator-1

Cat. No.:	HY-153952
CAS No.:	2757469-20-6
Molecular Formula:	C ₃₂ H ₃₁ FN ₆ O ₄
Molecular Weight:	582.62
Target:	TNF Receptor; Interleukin Related; Potassium Channel
Pathway:	Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Immuno modulator-1 (compound 22) inhibits TNF α and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC ₅₀ values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μ M ^[1] .		
IC₅₀ & Target	IL-2		
In Vitro	Immuno modulator-1 (compound 22) inhibits the proliferation of NCI-H929 human myeloma cell, with an IC ₅₀ of 0.6 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Immuno modulator-1 (compound 22) (1 mg/kg (IV), 5 mg/kg (PO); once) has an oral bioavailability of 30% in Male Sprague-Dawley rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Male Sprague-Dawley rats ^[1]	
	Dosage:	1 mg/kg (IV), 5 mg/kg (PO)	
	Administration:	IV (2 mL/kg), PO (10 mL/kg); once (Pharmacokinetic Analysis)	
	Result:	Pharmacokinetic Parameters of Immuno modulator-1 in male Sprague-Dawley rats ^[1] .	
		IV (1 mg/kg)	PO (5 mg/kg)
	C _{max} (ng/mL)		1437
	AUC ₀₋₂₄ (ng/mL <hmath>\timesh)</hmath>		13029
	CL (mL/min/kg)	2.2	
	V _{ss} (L/kg)	0.36	

F (%)

30%

REFERENCES

[1]. Chen Xiangyang, et al. Heterocyclic immunomodulator. Patent, WO2022007659A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA